a legal action launched to seek reparations from the State

a legal action launched to seek reparations from the State


Patients suffering from meningiomas (brain tumors) after taking the progestin Androcur are seeking compensation for the damage they have suffered, through legal action which aims to hold the State responsible.

Two requests were registered with the administrative court of Montreuil (Seine-Saint-Denis) on March 7, confirming information from the daily The world.

450 files

They “aim to recognize the fault of the National Medicines Safety Agency (ANSM), therefore of the State, in this major public health scandal” and obtain “compensation of 748,777 euros and 361,515 euros respectively” , explained Charles Joseph-Oudin, lawyer for the applicant. “Three other requests will be filed by the end of next week” and others will follow, he added.

His office holds 450 files concerning women who consumed Androcur and other progestins, Lutéran and Lutényl, authorized on the French market in 1974 and 1983 respectively, according to the lawyer.

“Fifty individual legal assessments have already been ordered” and “the twenty completed assessments all maintain the causal link between these meningiomas and the taking of medications,” he said.

A lack of information pointed out

These expert reports point to “above all, a lack of information” on the known risks of these treatments, a defect for which “the primary responsibility is that of the State (ANSM) in conjunction with the responsibility of the laboratories”, he underlined. . Contacted by AFP, the ANSM does not comment on the current procedure.

Me Joseph-Oudin and the Amavea association, which brings together 900 patients suffering from meningiomas after taking progestins, are seeking to discuss with the Ministry of Health so that “a compensation system is put in place as was done for the Médiator and Dépakine”, two health scandals which led to the creation of compensation funds for the victims.

The Amavea association hopes “that as many people as possible who have suffered serious harm from having consumed Androcur” will be compensated “up to the damage suffered”, indicated its president Emmanuelle Huet-Mignaton.

“Many women in the association” do not “have the financial means to launch this type of procedure”, some living on RSA after an operation and physical and/or cognitive after-effects, she underlined. Others are “waiting to see if it will succeed”.

Progestins are medications used in contraception, in the treatment of certain gynecological pathologies (uterine bleeding, endometriosis, etc.), or hormone replacement treatment for menopause and medically assisted procreation courses.

Androcur identified at risk since 2007

Meningiomas are tumors of the membranes that surround the brain. They are sometimes described as “benign”, not likely to degenerate into fatal cancers, but can cause serious neurological disabilities. Since the 2010s, certain progestins have been found to promote the appearance of these meningiomas.

The drug Androcur (cyproterone acetate) was the first to be identified as a risk, by a study by Professor Sébastien Froelich in 2007.

Theoretically indicated against excessive hair growth, but prescribed for decades by many doctors well beyond these indications – for example against endometriosis – the link of Androcur with meningiomas was clearly established in 2018.


Source link